Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.

Lisa Salvatore,Maria Bensi,Raffaella Vivolo,Ina Valeria Zurlo,Emanuela Dell'Aquila,Roberta Grande,Annunziato Anghelone,Alessandra Emiliani,Fabrizio Citarella,Maria Alessandra Calegari,Marta Ribelli,Michele Basso,Carmelo Pozzo,Giampaolo Tortora

Frontiers in oncology（2023）

引用 0|浏览31

暂无评分

摘要

Our results demonstrated a different benefit from third-line anti-EGFR-based therapy according to primary tumor site, confirming the role of L-sided tumor in predicting benefit from third-line anti-EGFR vs R/T. At the same time, no difference was observed in R-sided tumor.

查看译文

关键词

RAS/BRAF wild-type,Regorafenib,anti-egfr ab,colorectal cancer,primary tumor site,third-line therapy,trifluridine/tipiracil

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要